Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. 

At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma.

Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology.

For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW. 

Woodline Partners

BlackRock

Commodore Capital

Nextech Invest

Surveyor Capital

T. Rowe Price

Vida Ventures

Fidelity

Fidelity Management and Research Company

Google Ventures

Invus

Kronos Bio

This week our team enjoyed a lunch and learn with Martin Larke, Senior Scientist, Computational Biology, about how we are using machine learning to understand cellular response to stress. This is an important topic in oncology research and one that is central to Kronos Bios’ development of therapeutics that target deregulated transcription. Thanks Martin for such an engaging session!

Members of the Kronos Bio team were busy this week at the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. We shared our progress developing therapeutics that target deregulated transcription with investors and potential partners, including the latest on our first internally discovered molecule, KB-0742, a CDK9 inhibitor, as well as our new development candidate, KB-9558, a p300 KAT inhibitor. Thanks to everyone who met with us at #JPM. We appreciate your time, interest, and insights. 2024 is off to a good start!

- with Norbert Bischofberger, Barbara Kosacz, Jorge DiMartino, Christopher Dinsmore, Charles Lin, Sarah Connors, and Margaux Bennett

Wishing you and your family health, happiness and success in 2024!

Today, Kronos Bio announced updates to our pipeline including a new development candidate, KB-9558, which targets the KAT domain of p300, for use in multiple myeloma. To learn more, check out our press release here: https://lnkd.in/eNzhCYTK 

Richard Cutler, Ph.D., Vice President of Clinical Science at Kronos Bio, enjoyed presenting a Trial in Progress poster on our CDK9 inhibitor KB-0742 in triple negative breast cancer at the San Antonio Breast Cancer Symposium (SABCS). With more than 10,000 clinicians and scientists from all over the world, SABCS represents a great opportunity for scientific exchange on the latest in breast cancer research. Thank you Rich for representing Kronos Bio!

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	777K -	1.51M 93.82%	4.55M 202.12%	998K 78.07%	5.05M 405.71%	883K 82.50%
accumulated other comprehensive income loss		-18K -	-19K 5.56%	-39K 105.26%	-792K 1,930.77%	19K 102.40%
cash and cash equivalents	10.23M -	32.57M 218.50%	462.06M 1,318.67%	339.51M 26.52%	75.97M 77.62%	64.33M 15.33%
cash and short term investments	10.23M -	92.18M 801.47%	462.06M 401.24%	339.51M 26.52%	247.95M 26.97%	173.00M 30.23%
common stock	5K -	6K 20%	54K 800%	56K 3.70%	57K 1.79%	59K 3.51%
deferred revenue	9K -	818K 8,988.89%	4.97M 508.07%	9.06M 82.21%		9.58M -
deferred revenue non current						4.13M -
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory			-49.61M -	-816K 98.36%	-10.33M 1,166.42%
long term debt	493K -	211K 57.20%	31.12M 14,648.82%	31.65M 1.71%	28.74M 9.19%	25.38M 11.71%
long term investments		4.76M -	49.00M 929.00%		9.76M -	4.01M 58.87%
net debt	-9.46M -	-32.04M 238.89%	-430M 1,241.99%	-305.75M 28.90%	-44.88M 85.32%	-36.05M 19.67%
net receivables		198K -	612K 209.09%	816K 33.33%	572K 29.90%
other assets
other current assets	315K -		6.74M -	8.04M 19.34%	6.11M 24.10%	5.78M 5.32%
other current liabilities	247K -	56K 77.33%	2.39M 4,167.86%	1.46M 39.08%	14.09M 867.86%	11.34M 19.56%
other liabilities
other non current assets	273K -	427K 56.41%	2.19M 413.58%	2.14M 2.51%	3.19M 49.35%	577.00K 81.93%
other non current liabilities	18.11M -	122.98M 579.23%	2.47M 97.99%	1.10M 55.45%	209K 81%
othertotal stockholders equity	44K -	271K 515.91%	65.43M 24,042.44%	608.06M 829.39%	641.42M 5.49%	667.86M 4.12%
preferred stock			511.96M -
property plant equipment net	1.80M -	4.19M 133%	40.97M 876.82%	41.78M 1.99%	37.69M 9.79%	29.91M 20.65%
retained earnings	-7.34M -	-23.46M 219.43%	-111.91M 376.97%	-262.98M 135.00%	-396.19M 50.65%	-508.86M 28.44%
short term debt	278K -	317K 14.03%	942K 197.16%	2.11M 123.89%	2.35M 11.28%	2.89M 23.26%
short term investments		59.61M -	165.05M 176.87%	141.24M 14.43%	162.21M 14.85%	108.67M 33.01%
tax assets
tax payables	9K -	43K 377.78%	558K 1,197.67%		40K -	133K 232.50%
total assets	12.61M -	102.69M 714.06%	511.96M 398.57%	391.48M 23.53%	294.94M 24.66%	213.28M 27.69%
total current assets	10.54M -	93.30M 785.14%	419.80M 349.93%	347.55M 17.21%	244.29M 29.71%	178.78M 26.82%
total current liabilities	1.31M -	2.70M 105.72%	12.86M 376.68%	13.63M 5.99%	21.49M 57.68%	24.70M 14.94%
total debt	771K -	528K 31.52%	32.06M 5,972.35%	33.76M 5.30%	31.09M 7.91%	28.27M 9.07%
total investments		64.38M -	214.05M 232.50%	141.24M 34.02%	171.97M 21.76%	112.69M 34.47%
total liabilities	19.91M -	125.89M 532.29%	46.45M 63.11%	46.38M 0.14%	50.44M 8.75%	54.20M 7.46%
total liabilities and stockholders equity	12.61M -	102.69M 714.06%	511.96M 398.57%	391.48M 23.53%	294.94M 24.66%	213.28M 27.69%
total non current assets	2.07M -	9.38M 352.63%	92.16M 882.22%	43.92M 52.34%	50.65M 15.31%	34.50M 31.88%
total non current liabilities	18.60M -	123.19M 562.36%	33.59M 72.73%	32.75M 2.49%	28.95M 11.60%	29.51M 1.91%
total stockholders equity	-7.30M -	-23.20M 218.02%	465.52M 2,106.29%	345.10M 25.87%	244.50M 29.15%	159.08M 34.94%

COM:KRONOSBIO

Kronos Bio, Inc.

Last Close

0.87

22/11 21:00

Market Cap

75.72M

Beta: -

Volume Today

96.67K

Avg: -

Preview